Literature DB >> 27516099

Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.

Ming Shen1,2, Qilin Zhang1,2, Wenjuan Liu2,3, Meng Wang3,4, Jingjing Zhu2,5, Zengyi Ma1,2, Wenqiang He1,2, Shiqi Li1,2, Xuefei Shou1,2, Yiming Li2,3, Zhaoyun Zhang2,3, Hongying Ye2,3, Min He2,3, Bin Lu2,3, Zhenwei Yao2,6, Yun Lu7, Nidan Qiao1,2, Zhao Ye1,2, Yichao Zhang1,2, Yeping Yang2,3, Yao Zhao8,9, Yongfei Wang10,11.   

Abstract

INTRODUCTION: The difficulty of predicting the efficacy of somatostatin analogs (SSA) is not fully resolved. Here, we quantitatively evaluated the predictive value of relative signal intensity (rSI) on T1- and T2-weighted magnetic resonance imaging (MRI) for the short-term efficacy (3 months) of SSA therapy in patients with active acromegaly and assessed the correlation between MRI rSI and expression of somatostatin receptors (SSTR).
METHODS: This was a retrospective review of prospectively recorded data. Ninety-two newly diagnosed patients (37 males and 55 females) with active acromegaly were recruited. All patients were treated with pre-surgical SSA, followed by reassessment and transspenoidal surgery. rSI values were generated by calculating the ratio of SI in the tumor to the SI of normal frontal white matter. The Youden indices were calculated to determine the optimal cutoff of rSI to determine the efficacy of SSA. The correlation between rSI and expression of SSTR2/5 was analyzed by the Spearman rank correlation coefficient.
RESULTS: T2 rSI was strongly correlated with biochemical sensitivity to SSA. The cutoff value of T2 rSI to distinguish biochemical sensitivity was 1.205, with a positive predictive value (PPV) of 81.5 % and a negative predictive value (NPV) of 77.3 %. No correlation was found between MRI and tumor size sensitivity. Moreover, T2 rSI was negatively correlated with the expression of SSTR5.
CONCLUSION: T2 rSI correlates with the expression of SSTR5 and quantitatively predicts the biochemical efficacy of SSA in acromegaly.

Entities:  

Keywords:  Acromegaly; Magnetic resonance imaging; Relative signal intensity; Somatostatin analog; Somatostatin receptor

Mesh:

Substances:

Year:  2016        PMID: 27516099     DOI: 10.1007/s00234-016-1728-4

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  36 in total

1.  The volume of the sella turcica.

Authors:  G DI CHIRO; K B NELSON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-06

2.  Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Geir Ringstad; Stine L Fougner; Olivera Casar-Borota; Terje Nome; Jon Ramm-Pettersen; Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

3.  Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Authors:  Ming Shen; Xuefei Shou; Yongfei Wang; Zhaoyun Zhang; Jinsong Wu; Ying Mao; Shiqi Li; Yao Zhao
Journal:  Endocr J       Date:  2010-11-16       Impact factor: 2.349

4.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

5.  Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.

Authors:  S L Fougner; J Bollerslev; J Svartberg; M Øksnes; J Cooper; S M Carlsen
Journal:  Eur J Endocrinol       Date:  2014-05-27       Impact factor: 6.664

6.  Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas.

Authors:  Omar M Mahmoud; Atsushi Tominaga; Vishwa Jeet Amatya; Megu Ohtaki; Kazuhiko Sugiyama; Tetsuhiko Sakoguchi; Yasuyuki Kinoshita; Yukio Takeshima; Nobukazu Abe; Yuji Akiyama; Ahmad I El-Ghoriany; Abdel Karim H Abd Alla; Mostafa A M El-Sharkawy; Kazunori Arita; Kaoru Kurisu; Fumiyuki Yamasaki
Journal:  Eur J Radiol       Date:  2010-06-26       Impact factor: 3.528

7.  The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly.

Authors:  Ana Pokrajac; Andrew G Claridge; S K Abdul Shakoor; Peter J Trainer
Journal:  Eur J Endocrinol       Date:  2006-02       Impact factor: 6.664

Review 8.  Current treatment guidelines for acromegaly.

Authors:  S Melmed; I Jackson; D Kleinberg; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

Review 9.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

Review 10.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  16 in total

1.  Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.

Authors:  Burak Kocak; Emine Sebnem Durmaz; Pinar Kadioglu; Ozge Polat Korkmaz; Nil Comunoglu; Necmettin Tanriover; Naci Kocer; Civan Islak; Osman Kizilkilic
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

2.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 3.  T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.

Authors:  Iulia Potorac; Albert Beckers; Jean-François Bonneville
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Tumor T2 signal intensity and stalk angulation correlates with endocrine status in pituitary adenoma patients: a quantitative 7 tesla MRI study.

Authors:  John W Rutland; Puneet Pawha; Puneet Belani; Bradley N Delman; Corey M Gill; Teresa Brown; Khadeen Cheesman; Raj K Shrivastava; Priti Balchandani
Journal:  Neuroradiology       Date:  2020-01-10       Impact factor: 2.804

5.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

6.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

7.  The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI.

Authors:  Carla-Liana Scânteie; Daniel-Corneliu Leucuţa; Cristina Ghervan
Journal:  Med Pharm Rep       Date:  2021-10-30

8.  Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.

Authors:  Fabio Tortora; Alberto Negro; Ludovica F S Grasso; Annamaria Colao; Rosario Pivonello; Alessandra Splendiani; Luca Brunese; Ferdinando Caranci
Journal:  Gland Surg       Date:  2019-09

9.  Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.

Authors:  María R Alhambra-Expósito; Alejandro Ibáñez-Costa; Paloma Moreno-Moreno; Esther Rivero-Cortés; Mari C Vázquez-Borrego; Cristóbal Blanco-Acevedo; Álvaro Toledano-Delgado; María S Lombardo-Galera; Juan A Vallejo-Casas; Manuel D Gahete; Justo P Castaño; María A Gálvez; Raúl M Luque
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

10.  Usefulness of the Texture Signatures Based on Multiparametric MRI in Predicting Growth Hormone Pituitary Adenoma Subtypes.

Authors:  Chen-Xi Liu; Li-Jun Heng; Yu Han; Sheng-Zhong Wang; Lin-Feng Yan; Ying Yu; Jia-Liang Ren; Wen Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.